{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T13:31:42Z","timestamp":1769088702864,"version":"3.49.0"},"reference-count":9,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,8]],"date-time":"2022-02-08T00:00:00Z","timestamp":1644278400000},"content-version":"vor","delay-in-days":38,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nefrolog\u00eda (English Edition)"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.nefroe.2022.02.003","type":"journal-article","created":{"date-parts":[[2022,2,16]],"date-time":"2022-02-16T08:17:30Z","timestamp":1644999450000},"page":"28-32","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Blockade of interleukin-6 as a possible therapeutic target for AA amyloidosis"],"prefix":"10.1016","volume":"42","author":[{"given":"Marina","family":"Almenara-Tejederas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabiola","family":"Alonso-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenceslao Adri\u00e1n","family":"Aguillera-Morales","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"de la Prada-\u00c1lvares","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mercedes","family":"Salgueira-Lazo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.nefroe.2022.02.003_bib0005","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1056\/NEJMra023144","article-title":"Molecular mechanisms of amyloidosis","volume":"349","author":"Merlini","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nefroe.2022.02.003_bib0010","first-page":"93","article-title":"Amiloidosis secundaria (AA) asociada a tumoraciones benignas","volume":"28","author":"Bestard Matamorosa","year":"2008","journal-title":"Nefrolog\u00eda"},{"key":"10.1016\/j.nefroe.2022.02.003_bib0015","doi-asserted-by":"crossref","first-page":"84","DOI":"10.3109\/13506129.2014.1002031","article-title":"AA amyloidosis treated with tocilizumab: case series and updated literature","volume":"22","author":"Courties","year":"2015","journal-title":"Amyloid"},{"key":"10.1016\/j.nefroe.2022.02.003_bib0020","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1182\/blood-2014-04-570010","article-title":"A staging system for renal outcome and early markers of renal response to chemotheraphy in AL amyloidosis","volume":"124","author":"Palladini","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.nefroe.2022.02.003_bib0025","first-page":"S46","article-title":"Therapeutic blockade of interlukine-6 by tocilizumab in the management of AA amyloidosis and chronic inflammatory disorders: a case series and review of the literature","volume":"33","author":"Lane","year":"2015","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.nefroe.2022.02.003_bib0030","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1080\/13506129.2017.1301420","article-title":"Tocilizumab postopones the start of hemodialysis compared to conventional oral treatment in amyloid A amyloidosis patients with avanced insufficiency by suppresing serum SAA levels","volume":"24","author":"Uda","year":"2017","journal-title":"Amyloid"},{"key":"10.1016\/j.nefroe.2022.02.003_bib0035","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s00296-010-1430-5","article-title":"Effective and safe administration of tocilizumab to a patient with rheumatoid arthritis on haemodialysis","volume":"31","author":"Iwamoto","year":"2011","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.nefroe.2022.02.003_bib0040","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/1744-9987.12128","article-title":"Successful use of tocilizumab in a case of multicentric Castleman\u2019s disease and end-stage renal disease","volume":"18","author":"Nagai","year":"2014","journal-title":"Ther Apher Dial"},{"key":"10.1016\/j.nefroe.2022.02.003_bib0045","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1136\/annrheumdis-2014-206695","article-title":"Effectiveness and safety of tocilizumab therapy for patients with rheumatoid arthritis and renal insufficiency: a real-life registry study in Japan (the ACTRA-RI study)","volume":"74","author":"Mori","year":"2015","journal-title":"Ann Rheum Dis"}],"container-title":["Nefrolog\u00eda (English Edition)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2013251422000177?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2013251422000177?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T19:47:15Z","timestamp":1761853635000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2013251422000177"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":9,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S2013251422000177"],"URL":"https:\/\/doi.org\/10.1016\/j.nefroe.2022.02.003","relation":{},"ISSN":["2013-2514"],"issn-type":[{"value":"2013-2514","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Blockade of interleukin-6 as a possible therapeutic target for AA amyloidosis","name":"articletitle","label":"Article Title"},{"value":"Nefrolog\u00eda (English Edition)","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nefroe.2022.02.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.nefro.2021.01.006","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Espa\u00f1a, S.L.U. on behalf of Sociedad Espa\u00f1ola de Nefrolog\u00eda.","name":"copyright","label":"Copyright"}]}}